People with non-alcoholic fatty liver disease had serum thymosin beta-4 levels 42% lower than healthy controls, and the peptide was identified as an independent predictor of NAFLD diagnosis.
42% lower Tβ4 in NAFLDSerum thymosin beta-4 levels averaged 3.20 mg/L in NAFLD patients versus 5.53 mg/L in healthy controls — and each unit increase in Tβ4 was associated with a 66% lower odds of having NAFLD.
What the researchers found
Serum thymosin beta-4 was significantly lower in NAFLD patients (3.20 ± 0.98 mg/L) compared to healthy controls (5.53 ± 1.24 mg/L), a 42% reduction (P<0.001).
Multivariate logistic regression identified Tβ4 as an independent predictor of NAFLD (OR=0.343, 95% CI 0.240-0.491, P<0.001), meaning higher Tβ4 levels were strongly protective. Other independent predictors were LDL cholesterol, ALT, and IL-6.
Tβ4 showed significant negative correlations with total cholesterol (r=-0.163), triglycerides (r=-0.253), AST (r=-0.143), GGT (r=-0.245), and IL-6 (r=-0.155). Tβ4 was positively correlated with adiponectin (r=0.143), an anti-inflammatory and insulin-sensitizing hormone.
Why it matters
NAFLD affects roughly 25% of the global population and can progress to serious liver disease including cirrhosis and liver cancer. There is currently no approved drug treatment for NAFLD. Thymosin beta-4 is known for its tissue-healing and anti-inflammatory properties, and this finding that it's depleted in fatty liver disease suggests it could be both a diagnostic biomarker and a potential therapeutic target. If Tβ4 supplementation could prevent or reverse fatty liver, it would address an enormous unmet medical need.
How the study worked
Case-control study with 76 NAFLD patients and 130 healthy controls. Serum levels of Tβ4, IL-6, and adiponectin were measured by ELISA. Standard clinical measurements included fasting glucose, insulin, lipid profiles, and liver function tests. Multivariate logistic regression identified independent predictors of NAFLD. Correlation analyses assessed relationships between Tβ4 and metabolic, inflammatory, and liver function markers.
What this study cannot tell us
This is a cross-sectional case-control study, so it cannot determine whether low Tβ4 causes NAFLD or is a consequence of liver disease. The sample size is moderate (206 total) and from a single center. NAFLD diagnosis and severity staging methods are not detailed in the abstract. The correlation coefficients, while statistically significant, are relatively weak (r values of -0.14 to -0.25), suggesting Tβ4 explains only a small portion of the metabolic variance. The study did not assess whether Tβ4 supplementation would improve NAFLD.
How to read the evidence
This is a moderately sized case-control study with appropriate statistical analysis. While the association between low Tβ4 and NAFLD is clear and statistically robust, the cross-sectional design cannot establish causation. The evidence supports Tβ4 as a potential biomarker and therapeutic target, but interventional studies are needed.
When this study was published
Published in 2019, this study is about 7 years old. Since publication, interest in Tβ4's protective roles in various organs has continued to grow, and additional studies may have further explored the NAFLD connection.
The bigger picture
Thymosin beta-4 is one of the most abundant small peptides in the body, with known roles in wound healing, tissue repair, anti-inflammation, and cell migration. Its therapeutic potential has been explored in eye injuries, heart damage, and wound healing. This study adds NAFLD to the list of conditions where Tβ4 deficiency may contribute to disease, and where supplementation could potentially be beneficial. The inverse correlation between Tβ4 and inflammatory markers like IL-6 supports the idea that Tβ4 helps protect the liver from inflammation-driven damage.
Questions still open
- Would thymosin beta-4 supplementation prevent or reverse fatty liver disease in animal models or humans?
- Does Tβ4 depletion worsen as NAFLD progresses from simple steatosis to steatohepatitis and fibrosis?
- Could serum Tβ4 measurement be used as a non-invasive screening tool for NAFLD alongside existing liver function tests?
Common questions
What is thymosin beta-4 and what does it normally do in the body?
Does having low Tβ4 cause fatty liver disease?
Read the original research
Association between thymosin beta4 and non-alcoholic fatty liver disease.
Revista espanola de enfermedades digestivas, 111(4), 308-313
Citation
Jiang, Yong; Zhang, Ying; Ma, Cui-Hua; Zhang, Zhi-Guang; Li, Man; Ji, Ying-Lan; Qi, Feng-Xiang. (2019). Association between thymosin beta4 and non-alcoholic fatty liver disease.. Revista espanola de enfermedades digestivas, 111(4), 308-313. https://doi.org/10.17235/reed.2019.5927/2018